Singapore markets open in 7 hours

NVO Jan 2026 180.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
48.120.00 (0.00%)
As of 11:13AM EDT. Market open.
Full screen
Previous close48.12
Open48.12
Bid39.45
Ask40.95
Strike180.00
Expiry date2026-01-16
Day's range48.12 - 48.12
Contract rangeN/A
Volume5
Open interest17
  • Zacks

    ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

    Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

  • Barrons.com

    Don’t Fret About Eli Lilly and Novo’s Weight-Loss Drug Rivals, Analyst Says

    UBS expects the two to form a duopoly for years to come, predicting ‘limited penetration’ from new entrants until 2029..

  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat